Phase I ISIS-APOARx single and multiple dose study in volunteers.
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2015
At a glance
- Drugs ISIS APOARx (Primary)
- Indications Atherosclerosis
- Focus Adverse reactions
- Sponsors Isis Pharmaceuticals
- 03 Sep 2015 Trial identifier 2012-004909-27 is no longer appearing in the European Clinical Trials Database.
- 24 Jul 2015 Results published online in the Lancet.
- 22 Jul 2015 Results published in an Isis Pharmaceuticals media release.